Intrinsically disordered proteins

Synthesizing and Decoding Posttranslational Modifications of Disordered Proteins, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, February 7, 2024
Intrinsically disordered proteins, Drug design, TU Wien, Peptide, Knowledge, Institute of technology, Protein, Research, NMR, Fine chemical

TORONTO, Feb. 7, 2024 /PRNewswire-PRWeb/ -- Explore the structural impact of posttranslational modifications, chemical synthesis strategies, and their impact on novel drug design in this informative webinar.

Key Points: 
  • The featured speakers will share strategies for accessing proteins with site-specific posttranslational modifications for structural and biochemical experiments.
  • TORONTO, Feb. 7, 2024 /PRNewswire-PRWeb/ -- Explore the structural impact of posttranslational modifications, chemical synthesis strategies, and their impact on novel drug design in this informative webinar.
  • The impact of posttranslational modifications on protein structure is seldom investigated, leaving a gap in the knowledge of how posttranslational modifications modulate protein function.
  • Furthermore, the impact of posttranslational modifications on protein structure is seldom investigated, leaving a gap in the knowledge of how posttranslational modifications modulate protein function.

DP Technology Announces Nomination of Development Candidate, a Potential Best-in-Class Kv1.3 Inhibitor for Immunological Diseases Including IBD and AD

Retrieved on: 
Tuesday, January 30, 2024
Patient, D. E. Shaw Research, Simulation, Atopic dermatitis, Membrane, UC, Lilly, DESRES, RNA, Robots in Disguise, PPI, IBD, AI, Microsoft Dynamics 365, Algorithm, DMPK, Eli Lilly and Company, Drug development, GPX4, Antibody, Prevalence, Intrinsically disordered proteins, Calcineurin, Eurosport 1, KCNA3, Internally displaced person, Conditional sentence, TH1, Drug discovery, Inflammatory bowel disease, Vaccine

The nomination of novel Kv1.3 inhibitor DPT0218 for the treatment of various immunological diseases including IBD and AD.

Key Points: 
  • The nomination of novel Kv1.3 inhibitor DPT0218 for the treatment of various immunological diseases including IBD and AD.
  • Inhibition of Kv1.3 therefore offers a potential opportunity to specifically impair inflammatory immune cell activity and proliferation, including in antigen-activated T cells.
  • Long-lived memory T-cell populations, particularly tissue resident subsets, may contribute to the chronicity of IBD and represent a potential target for therapy[4].
  • It has shown positive results in preclinical animal models of various autoimmune diseases such as IBD and AD.

Peptone and The Institute of Oncology Research (IOR) Bellinzona Announce Collaborative Research Agreement

Retrieved on: 
Thursday, November 30, 2023
Biophysics, IOR, Research, Molecular oncology, Disease, Intrinsically disordered proteins, Protein, Patient, Prostate cancer, Health, Oncology, Therapy, MD, Doctor of Philosophy, Internally displaced person, Pharmaceutical industry, Peptide

LONDON and BELLINZONA, Switzerland, Nov. 30, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), and The Institute of Oncology Research (IOR) today announced the commencement of a collaborative sponsored research agreement in prostate cancer. The collaboration will focus on the identification and progression of novel targets in oncology using translational models to develop innovative medicines for patients suffering from prostate cancer.

Key Points: 
  • LONDON and BELLINZONA, Switzerland, Nov. 30, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), and The Institute of Oncology Research (IOR) today announced the commencement of a collaborative sponsored research agreement in prostate cancer.
  • The collaboration will focus on the identification and progression of novel targets in oncology using translational models to develop innovative medicines for patients suffering from prostate cancer.
  • "Our collaboration is an excellent example of efficient technology transfer process and a burgeoning research and biotech ecosystem in Ticino, Switzerland."
  • "We are delighted to partner with Peptone on this research collaboration focused on novel target discovery in prostate cancer.

Peptone and The Institute of Oncology Research (IOR) Bellinzona Announce Collaborative Research Agreement

Retrieved on: 
Thursday, November 30, 2023
Biophysics, IOR, Research, Molecular oncology, Disease, Intrinsically disordered proteins, Protein, Patient, Prostate cancer, Health, Oncology, Therapy, MD, Doctor of Philosophy, Internally displaced person, Pharmaceutical industry, Peptide

LONDON and BELLINZONA, Switzerland, Nov. 30, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), and The Institute of Oncology Research (IOR) today announced the commencement of a collaborative sponsored research agreement in prostate cancer. The collaboration will focus on the identification and progression of novel targets in oncology using translational models to develop innovative medicines for patients suffering from prostate cancer.

Key Points: 
  • LONDON and BELLINZONA, Switzerland, Nov. 30, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), and The Institute of Oncology Research (IOR) today announced the commencement of a collaborative sponsored research agreement in prostate cancer.
  • The collaboration will focus on the identification and progression of novel targets in oncology using translational models to develop innovative medicines for patients suffering from prostate cancer.
  • "Our collaboration is an excellent example of efficient technology transfer process and a burgeoning research and biotech ecosystem in Ticino, Switzerland."
  • "We are delighted to partner with Peptone on this research collaboration focused on novel target discovery in prostate cancer.

Peptone Expands Leadership Team with Key Executive Hires

Retrieved on: 
Thursday, September 28, 2023
University of Oxford, DNA, Laboratory, Specialization, Drug development, University, Therapy, Senior, Intrinsically disordered proteins, Chiron Corporation, Drug discovery, CSO, Head, Abbott Laboratories, Nuffield Department of Population Health, Gritstone bio, Inflammation, Antibody, Doctor of Philosophy, AstraZeneca, Drug design, Internally displaced person, Messenger, McKinsey & Company, Neuroscience, Cryogenic electron microscopy, Protein, MD, Biophysics, Chairperson, Jazz Pharmaceuticals, Biology, Growth, Imperial College London, Rucaparib, Exosome, DNA methylation, Research, Clovis Oncology, Health, A-DNA, SVP, PARP, Somerville College, Oxford, Disease, Management, Pharmaceutical industry, Medicine, Peptide, Immunology

LONDON and BELLINZONA, Switzerland, Sept. 28, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), today announced the appointment of key leaders to its Executive Management Team and Board of Directors. Patrik Foerch, PhD, has been appointed Chief Scientific Officer; David Lowe, PhD, joins as Senior Vice President of Protein Therapeutics; and Benjamin Owens, PhD, previously Chief Strategy Officer, has transitioned to the role of Chief Business Officer and will join Peptone's Board of Directors as Executive Director. Andrew Allen, MD, PhD, co-founder, President and CEO of Gritstone bio, has been appointed Board Chair.

Key Points: 
  • LONDON and BELLINZONA, Switzerland, Sept. 28, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), today announced the appointment of key leaders to its Executive Management Team and Board of Directors.
  • "I'm excited to join this incredible team to chart new territory with potential to open therapeutic opportunities across a broad range of diseases."
  • Prior to joining Peptone, he served as Vice President of Research at Evox Therapeutics, a company focused on the development of exosomes as therapeutics.
  • He has also held clinical development leadership positions at Chiron Corporation and Abbott Laboratories and worked at McKinsey & Company.

Peptone Expands Leadership Team with Key Executive Hires

Retrieved on: 
Thursday, September 28, 2023
University of Oxford, DNA, Laboratory, Specialization, Drug development, University, Therapy, Senior, Intrinsically disordered proteins, Chiron Corporation, Drug discovery, CSO, Head, Abbott Laboratories, Nuffield Department of Population Health, Gritstone bio, Inflammation, Antibody, Doctor of Philosophy, AstraZeneca, Drug design, Internally displaced person, Messenger, McKinsey & Company, Neuroscience, Cryogenic electron microscopy, Protein, MD, Biophysics, Chairperson, Jazz Pharmaceuticals, Biology, Growth, Imperial College London, Rucaparib, Exosome, DNA methylation, Research, Clovis Oncology, Health, A-DNA, SVP, PARP, Somerville College, Oxford, Disease, Management, Pharmaceutical industry, Medicine, Peptide, Immunology

LONDON and BELLINZONA, Switzerland, Sept. 28, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), today announced the appointment of key leaders to its Executive Management Team and Board of Directors. Patrik Foerch, PhD, has been appointed Chief Scientific Officer; David Lowe, PhD, joins as Senior Vice President of Protein Therapeutics; and Benjamin Owens, PhD, previously Chief Strategy Officer, has transitioned to the role of Chief Business Officer and will join Peptone's Board of Directors as Executive Director. Andrew Allen, MD, PhD, co-founder, President and CEO of Gritstone bio, has been appointed Board Chair.

Key Points: 
  • LONDON and BELLINZONA, Switzerland, Sept. 28, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), today announced the appointment of key leaders to its Executive Management Team and Board of Directors.
  • "I'm excited to join this incredible team to chart new territory with potential to open therapeutic opportunities across a broad range of diseases."
  • Prior to joining Peptone, he served as Vice President of Research at Evox Therapeutics, a company focused on the development of exosomes as therapeutics.
  • He has also held clinical development leadership positions at Chiron Corporation and Abbott Laboratories and worked at McKinsey & Company.

Bruker Announces Successful Customer Installations of First Two Compact 1.0 GHz NMR Systems to Advance Structural Biology

Retrieved on: 
Friday, February 3, 2023
Stem Cells, Medical Supplies, Biotechnology, Other Health, Health, Biometrics, Other Science, Medical Devices, Research, Science, Clinical Trials, Singular, GPCR, Instituto Universitario de Restauración del Patrimonio of the Universitat Politècnica de València, Molecular biology, Ascend, Intrinsically disordered proteins, Helium, ICTS, RNA, Hertz, University of Barcelona, CIC, Multimedia, RIKEN, NMR, Internally displaced person, Medical imaging, Bruker

Bruker today announced successful customer installations of two novel, compact 1.0 GHz NMR spectrometers for advanced structural and molecular biology applications well ahead of original schedules in late 2022.

Key Points: 
  • Bruker today announced successful customer installations of two novel, compact 1.0 GHz NMR spectrometers for advanced structural and molecular biology applications well ahead of original schedules in late 2022.
  • These new 1.0 GHz NMR magnets also have significantly reduced footprint, weight, and ceiling height requirements and fit into most single-story laboratories.
  • Dr. Falko Busse, President of the Bruker BioSpin Group, commented: "We are excited to announce the remarkably rapid delivery and customer acceptance of two 1.0 GHz NMR systems.
  • These low-maintenance, compact NMRs with lower helium consumption can bring the power of GHz NMR to many more laboratories.”

Bruker Introduces Enabling New Scientific Capabilities for Cell Biology and Pathobiology Research with High-Field NMR Innovations

Retrieved on: 
Monday, August 22, 2022
Software, Research, General Health, Pharmaceutical, Hardware, Medical Devices, Technology, Health Technology, Science, Biotechnology, Neurology, Health, EPR, Technology, 3D, Biotop, Research, CIC, University of Barcelona, University of Lille Nord de France, Organic acid, MAS, Neurodegeneration, Cell biology, HTS, Hertz, HCN, University, Helium, Cancer, Biochemistry, IDP, Department, Intrinsically disordered proteins, Microscopy, CNRS, University of Lille, NMR, Carbohydrate, Harvard Medical School, Solution, Arthanari, Precision medicine, Metalloprotein, Prion, Multimedia, Membrane protein, Crystallography, Proteomics, 14N, Magic angle spinning, Kelvin, Associate, Dana–Farber Cancer Institute, Instituto Universitario de Restauración del Patrimonio of the Universitat Politècnica de València, Pharmacology, Internally displaced person, Lyon, Conference, Phosphorylation, Ascend, Life, Medical imaging, Bruker

The new technology also facilitates cell biology research into highly dynamic intrinsically disordered proteins (IDPs) or protein regions that often play key roles in signaling pathways via phosphorylation, e.g.

Key Points: 
  • The new technology also facilitates cell biology research into highly dynamic intrinsically disordered proteins (IDPs) or protein regions that often play key roles in signaling pathways via phosphorylation, e.g.
  • It allows researchers to obtain essential information in crowded IDP spectral regions for the unambiguous assignment of IDP backbone resonances.
  • I am very excited to see which previously inaccessible but important scientific and pathobiology questions this innovative NMR technology can address.
  • Dr. Guido Pintacuda, CNRS Research Director and Director of the Lyon High-field NMR Center explained: The new Bruker 160 kHz MAS HCN probe will push structural, cellular and disease biology research into the next phase of the solid-state NMR scientific evolution.

Regeneron Announces the 2022 Winners of the Regeneron Prize for Creative Innovation

Retrieved on: 
Tuesday, July 26, 2022
Civic, Goal, Gene expression, Antibody, Perelman School of Medicine at the University of Pennsylvania, Time, Inflammation, University, Dow Jones, Biomedical Research, Thought, Laboratory, Degenerative disease, Berkeley, Twitter, Creativity, Neurodegeneration, Culture, Intrinsically disordered proteins, Eye, Regeneron Science Talent Search, Lists of diseases, ISEF, Curriculum, COVID-19, Allergy, NASDAQ, Cancer, Nature Structural & Molecular Biology, Biotechnology, Ageing, Review, Drug development, Technology, Publication, FDA, Infection, Science, SAGA, Patient, Homegrown, Pain, Washington University School of Medicine, Neurology, George Washington University School of Engineering and Applied Science, Secondary research, Medicine, Pharmaceutical industry, Vaccine, New York University, Research, Regeneron Pharmaceuticals, Nature

TARRYTOWN, N.Y., July 26, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.(NASDAQ:REGN) today announced the winners of the 10th annual Regeneron Prize for Creative Innovation, a competition designed to recognize excellence and creativity in biomedical research conducted by postdoctoral fellows and graduate students.

Key Points: 
  • TARRYTOWN, N.Y., July 26, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.(NASDAQ:REGN) today announced the winners of the 10th annual Regeneron Prize for Creative Innovation, a competition designed to recognize excellence and creativity in biomedical research conducted by postdoctoral fellows and graduate students.
  • Meagan Esbin, a graduate student from theUniversity of California at Berkeley, received a $10,000 prize as an honorable mention.
  • In total,$155,000in prize money and donations was awarded to winners, finalists and institutions to advance innovative scientific research.
  • Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro bono, and matching gift programs.

Bruker Announces Three New GHz NMR Systems Orders for Functional Structural Biology and Clinical Phenomics Research

Retrieved on: 
Monday, July 11, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, University of Barcelona, Solution, Hertz, Bruker, Molecular biology, Cell biology, Internally displaced person, Proteomics, Precision medicine, Metabolomics, Instituto Universitario de Restauración del Patrimonio of the Universitat Politècnica de València, RIKEN, Intrinsically disordered proteins, CIC, Utrecht University, Maintenance, Multimedia, Ascend, University, EPR, Conference, Research, Life, NMR, Microscopy, Laboratory, Medical imaging, Helium

At the Euromar 2022 Conference, Bruker announced three new customer orders for GHz systems, which will incorporate novel, compact 1.0 GHz NMR magnets for structural biology applications and clinical research in single-story laboratories.

Key Points: 
  • At the Euromar 2022 Conference, Bruker announced three new customer orders for GHz systems, which will incorporate novel, compact 1.0 GHz NMR magnets for structural biology applications and clinical research in single-story laboratories.
  • The new Ascend Evo 1.0 GHz NMR magnet, operating at 4.2 Kelvin, allows functional structural biology and clinical phenomics researchers to dive deeper into the structural details, binding and dynamics of molecular structures and complexes for fundamental cell biology and pathobiology research.
  • View the full release here: https://www.businesswire.com/news/home/20220711005260/en/
    Compact 1.0 GHz NMR magnet Ascend Evo for structural biology applications and clinical research in single-story laboratories (Graphic: Business Wire)
    A first new 1.0 GHz NMR order comes from the RIKEN Center for Biosystems Dynamics Research in Yokohama, Japan.
  • Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics.